RFM.F Sensorion SAS

Healthcare Biotechnology Frankfurt Exchange
0.1890 EUR
Close of Sep 17, 2026
5.29 32.50
Market cap
EUR 1.95M
P/E
-
P/B
0.98x
ROE
-66.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RFM.F undervalued?

Graham number

The Graham number of Sensorion SAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sensorion SAS fundamental analysis

No fundamental analysis for Sensorion SAS yet.

Sensorion SAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sensorion SAS

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a s…

Full company profile